CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript Summary
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript Summary
Generated $12.5 million in cash from operations and ended with $241 million in cash and cash equivalents.The following is a summary of the CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript:
以下是CareDx, Inc（CDNA）2024年第三季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
CareDx reported Q3 revenue of $82.9 million, a 23% year-over-year growth.
Adjusted EBITDA was $6.9 million, substantially above the EBITDA-neutral guide.
Generated $12.5 million in cash from operations and ended with $241 million in cash and cash equivalents.
CaredX公布的第三季度收入为8,290万美元，同比增长23％。
调整后的息税折旧摊销前利润为690万美元，大大高于息税折旧摊销前利润中性指南。
从运营中产生了1,250万澳元的现金，最终获得了2.41亿美元的现金及现金等价物。
Business Progress:
业务进展：
Delivered approximately 44,600 tests, up 16% from the previous year.
Added 15 of a planned 30 sales and marketing team members to promote transplant solutions.
Collaboration with the University of California Health System to implement MedActionPlan.
进行了大约44,600次测试，比上年增长了16％。
在计划的 30 名销售和营销团队成员中增加了 15 名，以推广移植解决方案。
与加州大学卫生系统合作实施医疗行动计划。
Opportunities:
机会：
Coverage from Medicare and Medicaid Services reaffirmed for solid organ transplant monitoring.
Expanded commercial covered lives by four million in Q3. Highmark Blue Cross Blue Shield recently expanded coverage for AlloSure Kidney and HeartCare.
医疗保险和医疗补助服务重申了实体器官移植监测的承保范围。
第三季度扩大的商业覆盖寿命增加了四百万人。Highmark 蓝十字蓝盾最近扩大了 AlloSure Kidney 和 HeartCare 的承保范围。
Risks:
风险：
No explicit risks detected.
未发现任何明显的风险。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
小贴士：本文由 AI 生成。无法完全保证内容的准确性。如需更全面的详情，请访问投资者关系网站。本文仅供投资者参考，不提供任何指导或建议建议。
